CA2350685A1 - Spray-type cosmetic composition and matrix used in said composition for dermal administration - Google Patents
Spray-type cosmetic composition and matrix used in said composition for dermal administration Download PDFInfo
- Publication number
- CA2350685A1 CA2350685A1 CA002350685A CA2350685A CA2350685A1 CA 2350685 A1 CA2350685 A1 CA 2350685A1 CA 002350685 A CA002350685 A CA 002350685A CA 2350685 A CA2350685 A CA 2350685A CA 2350685 A1 CA2350685 A1 CA 2350685A1
- Authority
- CA
- Canada
- Prior art keywords
- composition according
- composition
- ethylhexyl
- matrix
- aqueous solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 148
- 239000011159 matrix material Substances 0.000 title claims abstract description 56
- 230000002500 effect on skin Effects 0.000 title claims abstract description 31
- 239000002537 cosmetic Substances 0.000 title claims description 30
- 238000001035 drying Methods 0.000 claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 59
- 239000013543 active substance Substances 0.000 claims description 57
- 239000001856 Ethyl cellulose Substances 0.000 claims description 33
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical group CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 33
- 229920001249 ethyl cellulose Polymers 0.000 claims description 33
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 33
- 229940124532 absorption promoter Drugs 0.000 claims description 26
- -1 aliphatic fatty acid ester Chemical class 0.000 claims description 22
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 21
- 239000003125 aqueous solvent Substances 0.000 claims description 21
- 229920001577 copolymer Polymers 0.000 claims description 20
- 239000002904 solvent Substances 0.000 claims description 20
- 229920000642 polymer Polymers 0.000 claims description 17
- 229920002678 cellulose Polymers 0.000 claims description 16
- 239000001913 cellulose Substances 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 15
- 238000001704 evaporation Methods 0.000 claims description 15
- 238000005507 spraying Methods 0.000 claims description 14
- OUCGJMIVSYHBEC-UHFFFAOYSA-N 2-ethylhexyl 2-ethylhexanoate Chemical compound CCCCC(CC)COC(=O)C(CC)CCCC OUCGJMIVSYHBEC-UHFFFAOYSA-N 0.000 claims description 12
- 238000010521 absorption reaction Methods 0.000 claims description 12
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 12
- 230000008020 evaporation Effects 0.000 claims description 12
- 239000000194 fatty acid Substances 0.000 claims description 12
- 229930195729 fatty acid Natural products 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 9
- ASKIVFGGGGIGKH-UHFFFAOYSA-N 2,3-dihydroxypropyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(O)CO ASKIVFGGGGIGKH-UHFFFAOYSA-N 0.000 claims description 8
- 238000009835 boiling Methods 0.000 claims description 8
- 239000002464 receptor antagonist Substances 0.000 claims description 8
- 229940044551 receptor antagonist Drugs 0.000 claims description 8
- 101710151321 Melanostatin Proteins 0.000 claims description 7
- 239000002660 neuropeptide Y receptor antagonist Substances 0.000 claims description 7
- 239000007921 spray Substances 0.000 claims description 7
- 125000004423 acyloxy group Chemical group 0.000 claims description 5
- 239000005557 antagonist Substances 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 229940074052 glyceryl isostearate Drugs 0.000 claims description 4
- 229940100463 hexyl laurate Drugs 0.000 claims description 4
- 244000005700 microbiome Species 0.000 claims description 4
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 3
- 229920008347 Cellulose acetate propionate Polymers 0.000 claims description 3
- 241000187747 Streptomyces Species 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 239000001273 butane Substances 0.000 claims description 3
- 229920006217 cellulose acetate butyrate Polymers 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 3
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims description 3
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 claims description 3
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- SEWAAPWEWOCMKK-UHFFFAOYSA-N 2-(2-ethoxyethoxy)ethyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCOCCOCC SEWAAPWEWOCMKK-UHFFFAOYSA-N 0.000 claims 2
- DDGZCTKMHAYRKN-UHFFFAOYSA-N 2-ethylhexyl 12-acetyloxyoctadecanoate Chemical compound CCCCCCC(OC(C)=O)CCCCCCCCCCC(=O)OCC(CC)CCCC DDGZCTKMHAYRKN-UHFFFAOYSA-N 0.000 claims 2
- GLCFQKXOQDQJFZ-UHFFFAOYSA-N 2-ethylhexyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(CC)CCCC GLCFQKXOQDQJFZ-UHFFFAOYSA-N 0.000 claims 2
- QIVJGFWGDVLWQP-UHFFFAOYSA-N 2-ethylhexyl undec-10-enoate Chemical compound CCCCC(CC)COC(=O)CCCCCCCCC=C QIVJGFWGDVLWQP-UHFFFAOYSA-N 0.000 claims 2
- ZQXRINMCMHCYBD-UHFFFAOYSA-N 4-(2-ethylhexoxy)-4-oxobutanoic acid Chemical compound CCCCC(CC)COC(=O)CCC(O)=O ZQXRINMCMHCYBD-UHFFFAOYSA-N 0.000 claims 2
- 241000194108 Bacillus licheniformis Species 0.000 claims 2
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 claims 2
- JYZLSYFPFQTNNO-UHFFFAOYSA-N 2-octyldecan-1-ol Chemical compound CCCCCCCCC(CO)CCCCCCCC JYZLSYFPFQTNNO-UHFFFAOYSA-N 0.000 claims 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 11
- 210000003491 skin Anatomy 0.000 description 40
- 229960004667 ethyl cellulose Drugs 0.000 description 24
- 238000009472 formulation Methods 0.000 description 23
- 230000000694 effects Effects 0.000 description 13
- 239000007789 gas Substances 0.000 description 12
- 210000000689 upper leg Anatomy 0.000 description 12
- 238000009792 diffusion process Methods 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 238000002156 mixing Methods 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 description 5
- 208000035484 Cellulite Diseases 0.000 description 5
- 102400000064 Neuropeptide Y Human genes 0.000 description 5
- 206010049752 Peau d'orange Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000036232 cellulite Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 229940100554 isononyl isononanoate Drugs 0.000 description 5
- 210000003127 knee Anatomy 0.000 description 5
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 5
- 230000035515 penetration Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 3
- 238000010191 image analysis Methods 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000001294 propane Substances 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 241001484259 Lacuna Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- DJNTZVRUYMHBTD-UHFFFAOYSA-N Octyl octanoate Chemical compound CCCCCCCCOC(=O)CCCCCCC DJNTZVRUYMHBTD-UHFFFAOYSA-N 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 2
- 150000001298 alcohols Chemical group 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 210000001217 buttock Anatomy 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 230000004130 lipolysis Effects 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 230000008447 perception Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 230000037384 skin absorption Effects 0.000 description 2
- 231100000274 skin absorption Toxicity 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- LINXHFKHZLOLEI-UHFFFAOYSA-N trimethyl-[phenyl-bis(trimethylsilyloxy)silyl]oxysilane Chemical compound C[Si](C)(C)O[Si](O[Si](C)(C)C)(O[Si](C)(C)C)C1=CC=CC=C1 LINXHFKHZLOLEI-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- OHMHBGPWCHTMQE-UHFFFAOYSA-N 2,2-dichloro-1,1,1-trifluoroethane Chemical compound FC(F)(F)C(Cl)Cl OHMHBGPWCHTMQE-UHFFFAOYSA-N 0.000 description 1
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- GCHBANQNCWIASI-UHFFFAOYSA-N C(=O)=O.CC(C)C.CCC.CCCC Chemical compound C(=O)=O.CC(C)C.CCC.CCCC GCHBANQNCWIASI-UHFFFAOYSA-N 0.000 description 1
- DPCRCMPOKSFLEF-UHFFFAOYSA-N C(C)(=O)OC(CCCCCCCCCCC(=O)OCC(CCCC)CC)CCCCCC.OC(CCCCCCCCCCC(=O)OCC(CCCC)CC)CCCCCC.C(CCC(=O)O)(=O)OCC(CCCC)CC.C(CCCCCCCCC=C)(=O)OCC(CCCC)CC.C(CCCCCCC)C(CO)CCCCCCCC Chemical compound C(C)(=O)OC(CCCCCCCCCCC(=O)OCC(CCCC)CC)CCCCCC.OC(CCCCCCCCCCC(=O)OCC(CCCC)CC)CCCCCC.C(CCC(=O)O)(=O)OCC(CCCC)CC.C(CCCCCCCCC=C)(=O)OCC(CCCC)CC.C(CCCCCCC)C(CO)CCCCCCCC DPCRCMPOKSFLEF-UHFFFAOYSA-N 0.000 description 1
- JFDDCTNNCXGWIR-UHFFFAOYSA-N C(CCCCCCCCCCCCCCC)(=O)OC(C)C.C(CCCCCCCCCCCCC)(=O)OCCOCCOCC.C(CCCCCCCCCCCCC)(=O)OC(C)C.C(C)C(COC(C(CCCC)CC)=O)CCCC Chemical compound C(CCCCCCCCCCCCCCC)(=O)OC(C)C.C(CCCCCCCCCCCCC)(=O)OCCOCCOCC.C(CCCCCCCCCCCCC)(=O)OC(C)C.C(C)C(COC(C(CCCC)CC)=O)CCCC JFDDCTNNCXGWIR-UHFFFAOYSA-N 0.000 description 1
- UTVODUXIIFTYJM-UHFFFAOYSA-N CCCC.CCCCC.[N]=O.CCC(C)C.[N] Chemical compound CCCC.CCCCC.[N]=O.CCC(C)C.[N] UTVODUXIIFTYJM-UHFFFAOYSA-N 0.000 description 1
- UDHXJZHVNHGCEC-UHFFFAOYSA-N Chlorophacinone Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)C(=O)C1C(=O)C2=CC=CC=C2C1=O UDHXJZHVNHGCEC-UHFFFAOYSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 229940119154 Neuropeptide Y receptor antagonist Drugs 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 239000012871 anti-fungal composition Substances 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- SHZIWNPUGXLXDT-UHFFFAOYSA-N caproic acid ethyl ester Natural products CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000002788 crimping Methods 0.000 description 1
- 230000006341 curative response Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000012907 medicinal substance Substances 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- BPGXUIVWLQTVLZ-OFGSCBOVSA-N neuropeptide y(npy) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 BPGXUIVWLQTVLZ-OFGSCBOVSA-N 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000006200 vaporizer Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/70—Biological properties of the composition as a whole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9816422A FR2787712B1 (fr) | 1998-12-24 | 1998-12-24 | Composition cosmetique pulverisable et matrice utilisable dans cette composition pour une administration dermique |
| FR98/16422 | 1998-12-24 | ||
| PCT/FR1999/003051 WO2000038658A1 (fr) | 1998-12-24 | 1999-12-08 | Composition cosmetique pulverisable et matrice utilisable dans cette composition pour une administration dermique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2350685A1 true CA2350685A1 (en) | 2000-07-06 |
Family
ID=9534488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002350685A Abandoned CA2350685A1 (en) | 1998-12-24 | 1999-12-08 | Spray-type cosmetic composition and matrix used in said composition for dermal administration |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1140040A1 (pt) |
| JP (1) | JP2002533383A (pt) |
| KR (1) | KR20010089699A (pt) |
| CN (1) | CN1331587A (pt) |
| AU (1) | AU4520500A (pt) |
| BR (1) | BR9916814A (pt) |
| CA (1) | CA2350685A1 (pt) |
| FR (1) | FR2787712B1 (pt) |
| HU (1) | HUP0200095A2 (pt) |
| IL (1) | IL143144A0 (pt) |
| NO (1) | NO20013117L (pt) |
| PL (1) | PL365376A1 (pt) |
| TR (1) | TR200101569T2 (pt) |
| WO (1) | WO2000038658A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2754709B1 (fr) * | 1996-10-23 | 1999-03-05 | Sanofi Sa | Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition |
| GB0518769D0 (en) * | 2005-09-14 | 2005-10-19 | Medpharm Ltd | Topical formulations |
| JP4679350B2 (ja) * | 2005-11-24 | 2011-04-27 | 株式会社資生堂 | 水中油型乳化皮膚化粧料 |
| EP2153836A1 (en) * | 2008-08-04 | 2010-02-17 | Polichem S.A. | Film-forming liquid formulations for drug release to hair and scalp |
| KR101163862B1 (ko) * | 2010-03-23 | 2012-07-09 | (주)아모레퍼시픽 | 수중유형 나노 에멀젼 조성물 및 이의 제조방법 |
| ITCA20120004A1 (it) * | 2012-03-30 | 2012-06-29 | Abdelkrim Harchi | Unico reattivo disidratante e diafanizzante per istologia e citologia non nocivo e non tossico, biodegradabile 88%, a bassa volatilita' |
| CN115335024A (zh) * | 2020-03-02 | 2022-11-11 | Elc管理有限责任公司 | 使用纳米纤维用于修复皮肤的方法 |
| KR20220148884A (ko) * | 2020-03-02 | 2022-11-07 | 이엘씨 매니지먼트 엘엘씨 | 화장제의 전달, 조성물 및 이의 용도 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0289900A1 (en) * | 1987-04-30 | 1988-11-09 | Abbott Laboratories | Topical antibacterial compositions |
| FR2732223B1 (fr) * | 1995-03-30 | 1997-06-13 | Sanofi Sa | Composition pharmaceutique pour administration transdermique |
| FR2754709B1 (fr) * | 1996-10-23 | 1999-03-05 | Sanofi Sa | Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition |
-
1998
- 1998-12-24 FR FR9816422A patent/FR2787712B1/fr not_active Expired - Fee Related
-
1999
- 1999-12-08 KR KR1020017008101A patent/KR20010089699A/ko not_active Application Discontinuation
- 1999-12-08 CN CN99814967A patent/CN1331587A/zh active Pending
- 1999-12-08 BR BR9916814-6A patent/BR9916814A/pt not_active Application Discontinuation
- 1999-12-08 AU AU45205/00A patent/AU4520500A/en not_active Abandoned
- 1999-12-08 HU HU0200095A patent/HUP0200095A2/hu unknown
- 1999-12-08 TR TR2001/01569T patent/TR200101569T2/xx unknown
- 1999-12-08 CA CA002350685A patent/CA2350685A1/en not_active Abandoned
- 1999-12-08 JP JP2000590612A patent/JP2002533383A/ja not_active Withdrawn
- 1999-12-08 PL PL99365376A patent/PL365376A1/xx not_active Application Discontinuation
- 1999-12-08 EP EP99973534A patent/EP1140040A1/fr not_active Withdrawn
- 1999-12-08 WO PCT/FR1999/003051 patent/WO2000038658A1/fr not_active Application Discontinuation
- 1999-12-08 IL IL14314499A patent/IL143144A0/xx unknown
-
2001
- 2001-06-21 NO NO20013117A patent/NO20013117L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| FR2787712A1 (fr) | 2000-06-30 |
| EP1140040A1 (fr) | 2001-10-10 |
| AU4520500A (en) | 2000-07-31 |
| NO20013117L (no) | 2001-08-24 |
| WO2000038658A1 (fr) | 2000-07-06 |
| CN1331587A (zh) | 2002-01-16 |
| BR9916814A (pt) | 2001-10-16 |
| PL365376A1 (en) | 2005-01-10 |
| IL143144A0 (en) | 2002-04-21 |
| NO20013117D0 (no) | 2001-06-21 |
| KR20010089699A (ko) | 2001-10-08 |
| TR200101569T2 (tr) | 2001-10-22 |
| FR2787712B1 (fr) | 2002-08-30 |
| HUP0200095A2 (hu) | 2002-05-29 |
| JP2002533383A (ja) | 2002-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080019927A1 (en) | Compositions and methods for dermally treating neuropathy with minoxidil | |
| US6010716A (en) | Pharmaceutical composition for transdermal administration | |
| TWI225407B (en) | An acidified composition for topical treatment of nail and skin conditions | |
| US8741332B2 (en) | Compositions and methods for dermally treating neuropathic pain | |
| AU2006332066B2 (en) | Use of film-forming hair-care polymers from the group of polyurethanes and pharmaceutical preparations and plasters containing said polymers | |
| US20030152611A1 (en) | Pharmaceutical compositions for transdermal administration of anti-inflammatory agents | |
| US20070196293A1 (en) | Compositions and methods for treating photo damaged skin | |
| KR101709489B1 (ko) | 레티노이드를 포함하는 조성물 및 피부 상태를 처리하는 방법 | |
| US20060088497A1 (en) | Topical skin care composition | |
| Gennari et al. | Medicated foams and film forming dosage forms as tools to improve the thermodynamic activity of drugs to be administered through the skin | |
| CA2350685A1 (en) | Spray-type cosmetic composition and matrix used in said composition for dermal administration | |
| KR20230097052A (ko) | 개선된 효능을 갖는 백반증 병변의 치료 방법 | |
| EP4285931A1 (en) | Composition for external application | |
| KR20180130178A (ko) | 리포좀 및 이를 포함하는 화장료 조성물 | |
| MXPA01006463A (en) | Spray-type cosmetic composition and matrix used in said composition for dermal administration | |
| Al-Jarsha et al. | A Review on Film Forming Drug Delivery Systems | |
| KR102566124B1 (ko) | 초음파 미용기기용 겔 화장료 조성물 및 이의 제조방법 | |
| EP3692981B1 (en) | Topical composition for use in the treatment of psoriasis | |
| JP2003335658A (ja) | 敏感肌用の化粧料 | |
| MX2007013912A (es) | Administracion de baja dosis de una composicion topica. | |
| JP2003055185A (ja) | 皮膚外用剤 | |
| WO2022098320A1 (en) | Topical pharmaceutical compositions containing minoxidil and relevant excipients | |
| Sholikhah et al. | Comparative study of nanoemulsion gel and essential oil from cassumunar ginger (Zingiber cassumunar Roxb.) as a topical antiobesity: In vivo study in mice | |
| WO2024098062A2 (en) | Topical oxybutynin for hot flashes | |
| Bagul et al. | Emulgel-A Novel Advance for Skin Disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |